Novo ends inhaled-insulin development

01/14/2008 | Bloomberg

Novo Nordisk A/S has ended development of AERx, its investigational insulin inhaler. "We have realized that the trend is for physicians to start treatment with something simple rather than a device that has to be loaded with insulin for each mealtime use," Novo chief scientific officer Mads Krogsgaard Thomsen said in a telephone interview.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park